David A. Siegel T Scan Therapeutics, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TCRX
# of Institutions
89Shares Held
41.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.22MShares$23 Million9.31% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$22.1 Million1.08% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$19.7 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.4MShares$19.4 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$13.2 Million0.47% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $83.5M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...